Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NPCE

NeuroPace, Inc.

Healthcare | Medical - Devices

No licensed closing price on file for NPCE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.65

NeuroPace, Inc. (NASDAQ: NPCE) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 01:49 UTC.

What NeuroPace, Inc. does

The company manufactures the RNS System, a brain-responsive neuromodulation device designed to treat drug-resistant epilepsy by continuously monitoring brain electrical activity and delivering electrical pulses to prevent seizures before they occur. The RNS System is currently approved in the United States for adults with drug-resistant focal epilepsy and is the only commercially available device that records continuous brain activity data, allowing clinicians to monitor patients remotely and optimize treatment decisions.

Summarized from NeuroPace, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.65
Debt/equity4.08

Revenue, margins & earnings

FY2021: net loss $36M on revenue $45M$45MFY2021FY2022: net loss $47M on revenue $46M$46MFY2022FY2023: net loss $33M on revenue $65M$65MFY2023FY2024: net loss $27M on revenue $80M$80MFY2024FY2025: net loss $21M on revenue $100M$100MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-25
  • 2026-09-25CHIEF MEDICAL OFFICERTax withholding-335$4.7K
  • 2026-09-21Chief Financial OfficerTax withholding-1,162$16.6K
  • 2026-09-04CHIEF EXECUTIVE OFFICERTax withholding-1,310$19.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does NeuroPace, Inc. do?

The company manufactures the RNS System, a brain-responsive neuromodulation device designed to treat drug-resistant epilepsy by continuously monitoring brain electrical activity and delivering electrical pulses to prevent seizures before they occur.

When did NPCE last file with the SEC?

NeuroPace, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:49 UTC. This page is also available as JSON at /api/data?ticker=NPCE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NPCE and 5,000+ tickers.

Create a free account — keep NPCE
For your agent
GET /api/data?ticker=NPCE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt